Cargando…

Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents

Primary mediastinal B cell lymphoma (PMBL) is characterized by specific molecular hallmarks including the expression of B Cell Lymphoma factor 6 (BCL6) and the presence of the activated Signal Transducers and Activators of Transcription factor 6 (STAT6). Recently we have shown that combined targetin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Häberle, Marie-Therese, Kelsch, Elena, Dorsch, Karola, Möller, Peter, Ritz, Olga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278300/ https://www.ncbi.nlm.nih.gov/pubmed/25594020

Ejemplares similares

STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)
por: Ritz, Olga, et al.
Publicado: (2013)

Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
por: Schlager, Stefanie, et al.
Publicado: (2020)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression
por: Liu, Junye, et al.
Publicado: (2012)

MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells
por: Ashofteh, Nooshin, et al.
Publicado: (2021)

Rapid conditional knock-down–knock-in system for mammalian cells
por: Hölzel, Michael, et al.
Publicado: (2007)

Knock-Down of PRAME Increases Retinoic Acid Signaling and Cytotoxic Drug Sensitivity of Hodgkin Lymphoma Cells
por: Kewitz, Stefanie, et al.
Publicado: (2013)

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma
por: Dupont, Thibault, et al.
Publicado: (2015)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma
por: Mahmoud, Hanan Mohamed, et al.
Publicado: (2011)

Deficiency of the Transcriptional Repressor B Cell Lymphoma 6 (Bcl6) Is Accompanied by Dysregulated Lipid Metabolism
por: LaPensee, Christopher R., et al.
Publicado: (2014)

Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation
por: Yang, Haopeng, et al.
Publicado: (2019)

The epigenetic regulator CTCF modulates BCL6 in lymphoma
por: Batlle-López, Ana, et al.
Publicado: (2015)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Expression of c-Myc, Bcl2, Bcl6, and Cyclin D1 in High-Grade B-Cell Lymphoma
por: Ali, Seemal, et al.
Publicado: (2022)

Why are the phenotypes of TRAF6 knock-in and TRAF6 knock-out mice so different?
por: Petrova, Tsvetana, et al.
Publicado: (2022)

A purine scaffold Hsp90 inhibitor destabilizes Bcl6 and has specific anti-tumor activity in Bcl6 dependent B-cell lymphomas
por: Cerchietti, Leandro C, et al.
Publicado: (2009)

DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
por: Akpa, Chidimma Agatha, et al.
Publicado: (2019)

B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers
por: McLachlan, Tabitha, et al.
Publicado: (2022)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas
por: Lai, Anne Y., et al.
Publicado: (2010)

Knock-down of Hdj2/DNAJA1 co-chaperone results in an unexpected burst of tumorigenicity of C6 glioblastoma cells
por: Meshalkina, Darya A., et al.
Publicado: (2016)

Trans-presentation of IL-15 modulates STAT5 activation and Bcl-6 expression in T(H)1 cells
por: Cooley, Ian D., et al.
Publicado: (2015)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
por: Cayrol, Florencia, et al.
Publicado: (2017)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

BCL-6 and other genomic alterations in non-Hodgkin's lymphoma (NHL).
por: Butler, M., et al.
Publicado: (1997)

Impact of GLO1 Knock Down on GLUT4 Trafficking and Glucose Uptake in L6 Myoblasts
por: Engelbrecht, Britta, et al.
Publicado: (2013)

Intracellular Accumulation of Methylglyoxal by Glyoxalase 1 Knock Down Alters Collagen Homoeostasis in L6 Myoblasts
por: Stratmann, Bernd, et al.
Publicado: (2017)

Knock-down of ZBED6 in insulin-producing cells promotes N-cadherin junctions between beta-cells and neural crest stem cells in vitro
por: Wang, Xuan, et al.
Publicado: (2016)

Gene amplification in human cells knocked down for RAD54
por: Ruiz-Herrera, Aurora, et al.
Publicado: (2011)

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
por: Ye, Qing, et al.
Publicado: (2015)

Variant Translocation of the BCL6 Gene to Immunoglobulin k Light Chain Gene in B‐Cell Lymphoma
por: Suzuki, Ken, et al.
Publicado: (1994)

The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma
por: Shi, Yaoyao, et al.
Publicado: (2016)

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Mitobe, Masaki, et al.
Publicado: (2018)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Knocked down a Notch with age
por: LeBrasseur, Nicole
Publicado: (2003)

Knocking down Disease with siRNAs
por: Dykxhoorn, Derek M., et al.
Publicado: (2006)

Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
por: Cayrol, Florencia, et al.
Publicado: (2017)

Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?
por: Walker, Sarah R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3ktif8hk1hfusjih1u35gclbbd